Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management - 15/05/26
, Ajay Duseja, MD, DM b, Jian-Gao Fan, MD, PhD c, Alexander Nersesov, MD, ScD d, Atsushi Nakajima, MD, PhD eRésumé |
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis, represent rapidly growing health challenges in Asia. This review summarizes the epidemiology, genetic predispositions, clinical features, diagnostic approaches, and treatment strategies for MASLD across diverse Asian populations. Distinctive aspects include high prevalence of lean and nonobese MASLD, strong influence of risk variants, such as PNPLA3, and unique mortality patterns compared with Western cohorts. Diagnostic practices must consider region-specific body mass index thresholds, limited access to noninvasive tests, including elastography, and coexisting viral hepatitis. Greater inclusion of Asian patients in clinical trials is essential for tailored management strategies.
Le texte complet de cet article est disponible en PDF.Keywords : Metabolic dysfunction-associated steatotic liver disease, Metabolic dysfunction-associated steatohepatitis, Asia, Lean MASLD, Non-obese MASLD, SNPs, Epidemiology
Plan
Vol 30 - N° 2
P. 495-511 - mai 2026 Retour au numéro
Article précédent
- Metabolic Dysfunction-Associated Steatohepatitis in the Middle East: Clinical Challenges and Strategies to Bridge the Gap
- Saleh A. Alqahtani, Carolin V. Schneider, Saeed Hamid, Faisal Abaalkhail
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa : From Burden to Action
- Mohamed El-Kassas, C. Wendy Spearman, Manal El-Sayed, Zobair M. Younossi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?